Lido Advisors
AQST icon

Lido Advisors’s Aquestive Therapeutics AQST Stock Holding History

Lido Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$896K Buy
+215,316
New +$906K ﹤0.01% 1147
2026
Q1 		– Sell
-29,962
Closed -$167K – 1948
2025
Q4 		$167K Hold
29,962
– – ﹤0.01% 1795
2025
Q3 		$167K Buy
+29,962
New +$130K ﹤0.01% 1704

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Lido Advisors's AQST Position: Q2 2026 in Review

Lido Advisors opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 215,316 shares worth $896K. The stake represents ﹤0.01% of the portfolio and ranks #1147 among its holdings. This is a return to the name: Lido Advisors previously reported a position in AQST as recently as Q4 2025.

Lido Advisors first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Lido Advisors held 215,316 shares of Aquestive Therapeutics worth $896K as of Q2 2026.
  • Aquestive Therapeutics was a new Lido Advisors position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1147 holding.
  • Lido Advisors first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.